Aim: To examine the effects of tanshinone IIA, the main effective component of Salvia miltiorrhiza (known as 'Danshen' in traditional Chinese medicine) on angiotensin II (Ang II)-mediated cardiomyocyte apoptosis. Methods: Rat neonatal cardiomyocytes were primarily cultured with Ang II or Ang II plus tanshinone IIA. Myocyte apoptosis was evaluated by caspase-3 activity and DNA strand break level with TdT-mediated dUTP nick-end labeling (TUNEL) staining. Western blot analysis was employed to determine the related protein expression and flow cytometry assay was used to determine the TUNEL positive cells and the intracellular reactive oxygen species (ROS) production. SiRNA targeted to Akt was used. Results: Ang II (0.1 µmol/L) remarkably increased caspase-3 activity, TUNEL positive cells, and cleaved caspase-3 and cytochrome c expression, but reduced Bcl-X L expression. These effects were effectively antagonized by pretreatment with tanshione IIA (1−3 µmol/L). Tanshinone IIA had no effect on basal ROS level, while attenuated the ROS production by Ang II. Interestingly, tanshione IIA significantly increased the phosphorylated Akt level, which was countered by the PI3K antagonist wortmannin or LY294002. Knockdown of Akt with Akt siRNA significantly reduced Akt protein levels and tanshinone IIA protective effect. Conclusion: Tanshinone IIA prevents Ang II-induced apoptosis, thereby suggesting that tanshinone IIA may be used for the prevention of the cardiac remodeling process.
Introduction
Apoptosis or programmed cell death is thought to play a crucial role in a variety of pathological situations [1] . The importance of apoptosis in heart failure has been recognized for over a decade [2] . The chronic release of reactive oxygen species (ROS) has been recently linked to the development of left ventricular hypertrophy and progression of heart failure [3] . Activation of the local and systemic renin-angiotensin system is closely related to increased morbidity in heart failure [4] . Pharmacological blockade of the renin-angiotensin system is beneficial in patients with heart failure [4] . Experiments using cultured cardiomyocytes have demonstrated that apoptosis can be stimulated in vitro by angiotensin II (Ang II) [5, 6] . Ang II induces cardiomyocyte apoptosis, which contributes to heart failure possibly through enhanced ROS production [6] . Therefore, it is important to develop agents that inhibit cardiomyocyte apoptosis induced by Ang II and, as a result, improve cardiac dysfunction.
Tanshinone IIA extracted from Danshen, a popular medicinal herb used in traditional Chinese medicine, exhibits a variety of cardiovascular activities, including vasorelaxation, and cardioprotective effects [7] [8] [9] [10] . However, the pretreatment effects and mechanisms of tanshinone IIA on cardioprotection are not well understood. Akt is known to regulate many survival pathways in cardiac cells [11] and has been reported to preserve cardiac function and prevent cardiac injury [12] . Therefore, the present study was set to evaluate the protective effect of tanshinone IIA on Ang II-induced cardiomyocyte apoptosis and to identify whether the underlying mechanisms are associated with the Akt-dependent pathway. 
Cell culture
Primary cultures of neonatal rat cardiomyocytes were prepared as previously described [13] . The study was conducted in accordance with the Declaration of Helsinki and/or with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the United States National Institutes of Health and was approved by the Institutional Animal Care and Use Committee of China Medical University (LAC-94-0069). The purity of the obtained myocyte cultures (>95%) was determined by immunofluorescence microscopy. We counted all nuclei stained by 4',6-diamidino-2-phenyindole (DAPI) (Sigma-Aldrich) and all cells that stained positive for α-actinin (Sigma-Aldrich). The culture medium was replaced after 24 h with serum-free medium consisting of DMEM (10 μg/mL), insulin (10 μg/mL), and BrdU (0.1 mmol/L) and exposed to the agents as indicated.
Caspase-3 activity assay
For the caspase-3 activity assay, the caspase-3 substrate rhodamine-110 (Z-DEVD-R110) was used as a prefluorescent substrate. The activity of caspase-3 was determined using a commercially available kit (Promega; Madison, WI, USA) according to the manufacturer's instructions. Briefly, after 48-h treatments with Ang II, tanshinone IIA, Ang II+tanshinone IIA, or vehicle, the caspase-3 reagent was added and incubated for 10 h. Levels of release of rhodamine-110 were measured with a luminescence spectrometer LS55 (Perkin-Elmer, Waltham, MA, USA) at an excitation wavelength of 499 nm and an emission wavelength of 521 nm.
TUNEL assay
Ang II-mediated apoptosis in cardiomyocytes was detected with enzymatic labeling of DNA strand breaks, which were identified with terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) stain. TUNEL staining was performed with a Cell Death Detection kit (Roche, Mannheim, Germany) according to the manufacturer's directions. The apoptotic ratio was measured by flow cytometry according to the manufacturer's instructions.
Western blot analysis
Western blot analysis was performed as previously described [14] . Membranes were blocked in 10 mmol/L Tris (pH 7.5), 100 mmol/L NaCl, and 0.1% Tween 20 containing 5% nonfat dry milk, followed by incubation with the primary antibody. Membranes were washed three times and incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (1:5000 dilutions), and enhanced chemiluminescence (Amersham Biosciences Corp, NJ, USA), and bands were quantified with densitometry.
Flow cytometric assay of 2′,7′-dichlorodihydrofluorescein oxidation The determination of intracellular ROS production was based on the oxidation of 2',7'-dichlorodihydrofluorescein (DCFH) to fluorescent 2',7'-dichlorofluorescein (DCF), as described previously [15] . DCFH was added to the cells at a final concentration of 10 μmol/L and incubated for 30 min at 37 °C. The cells were then washed once with PBS and maintained in 1-mL culture medium. Following drug treatment, the medium was aspirated and the cells were washed twice with PBS, and then dissociated with trypsin. Cellular fluorescence was determined by flow cytometry (FACS-SCAN, Becton-Dickinson, Franklin Lakes, NJ, USA). Cells were excited with an argon laser at 488 nm, and measurements were taken at 510-540 nm.
Short interfering RNA (siRNA) transfection Akt siRNAs were purchased from Santa Cruz Biotechnology. Akt siRNAs and mock control oligonucleotides were transfected using the Lipofectamine (Invitrogen) reagent according to the manufacturer's instructions. The final concentration of the Akt siRNAs for transfection was 100 nmol/L. Transfected cells were washed with PBS, and then incubated in new culture media for an additional 48 h for Ang II treatment and Western blot assays.
Statistical analysis
Results are expressed as mean±SEM. Statistical analysis was performed using Student's t test or analysis of variance (ANOVA) with the Prism version 3.00 for Windows (GraphPad Software, San Diego, CA, USA). A value of P<0.05 was considered to be statistically significant.
Results
The effect of tanshinone IIA on Ang II-induced cardiomyocyte apoptosis Using TUNEL staining with flow cytometry, we observed the effects of Ang II at a series of concentrations (0.001, 0.01, 0.1, and 1 µmol/L). Ang II at 0.1-1 µmol/L appeared to have the strongest action ( Figure 1A ). We also observed the effects of Ang II (0.1 µmol/L) at different incubation times (12, 24, 36 , and 48 h) and found that Ang II exerted the most significant actions in inducing apoptotic cell death at an incubation time of 48 h ( Figure 1B) . Therefore, we present the data obtained from 0.1 µmol/L Ang II and 48 h of incubation in this study. Recent work has supported a central role for members of the caspase family, especially caspase-3, as effectors of apoptosis [16] . To examine whether tanshinone IIA attenuates apoptosis induced by Ang II, we measured the caspase-3 activity in cells pretreated with tanshinone IIA. As shown in Figure 1C , the caspase-3 activity in Ang II-treated cells (0.1 and 1 µmol/L; 48 h) was significantly increased compared with vehicle-treated cells. Cardiomyocytes pretreated with tanshinone IIA (1, 3, and 10 µmol/L) for 30 min, followed by 0.1 µmol/L Ang II for 48 h, significantly inhibited the activation of caspase-3 by Ang II ( Figure 1D) .
The protective effect of tanshinone IIA against Ang IIinduced apoptosis in cardiomyocytes was further examined using TUNEL staining with flow cytometry (Figure 2A ). Cardiomyocytes were pretreated with tanshinone IIA for 30 min, followed by 0.1 µmol/L Ang II for 48 h. Treatment with Ang II (0.1 µmol/L) for 48 h increased the percentage of apoptotic cells (Figure 2A ). Tanshinone IIA treatment alone did not affect normal cell survival. In contrast, the pretreatment with tanshinone IIA (3, and 10 µmol/L) markedly decreased the number of apoptotic cells induced by Ang II (Figure 2A ). The influence of tanshinone IIA on apoptotic markers, such as cleaved caspase, cytochrome c, and Bcl-x L , was further evaluated by Western blot analysis ( Figure 2B ). As shown in Figure  2B , the levels of cleaved caspase-3 and cytosolic cytochrome c were greatly elevated in the cells treated with 0.1 µmol/L Ang II for 12 h. Pretreatment with tanshinone IIA at 3 µmol/L significantly reduced the amount of cleaved caspase-3 and cytosolic cytochrome c, as compared with that in Ang II-treated alone cells. In contrast, the expression of Bcl-x L was reduced by Ang II treatment, which was also recovered by tanshinone IIA pretreatment. These results indicate that the pretreatment with tanshinone IIA inhibited Ang II-induced cardiomyocyte apoptosis.
The influence of tanshinone IIA on Ang II-induced ROS generation in cardiomyocytes To evaluate the mechanism of the protective effect of tanshinone IIA on Ang II-induced apoptosis, the influence of tanshinone IIA on Ang II-induced ROS generation was monitored. We examined whether tanshinone IIA prevents Ang II-induced ROS formation. Tanshinone IIA-pretreated cells were then treated with 0.1 µmol/L Ang II for 1 h. The Ang II-induced increases in intracellular ROS were revealed by measuring the fluorescent intensities of DCF. As shown in Figure 3A and 3B, pretreatment with tanshinone IIA or the ROS scavenger N-acetylcysteine (NAC; 5 mmol/L) significantly inhibited Ang II-induced ROS production. These results indicate that the pretreatment with tanshinone IIA inhibited Ang II-induced ROS production in cardiomyocytes. Effects of tanshinone IIA on phospho-Akt in cardiomyocytes Akt is known to have an inhibitory effect on apoptosis in several cell types including cardiomyocytes [12] . To determine the effects of tanshinone IIA on Akt phosphorylation in rat cardiomyocytes, the amount of phospho-Akt (for serine 473) was measured. As shown in Figure 4A , tanshinone IIA (3 µmol/L) increased the serine phosphorylation of Akt from 5 to 60 min in cardiomyocytes. Since Akt is one of the downstream effectors of PI3K, we next examined the effects of PI3K inhibitors on Akt phosphorylation. Pretreatment with the PI3K inhibitors wortmannin (Wort; 100 nmol/L) and LY294002 (LY; 10 nmol/L) inhibited the tanshinone IIAincreased Akt phosphorylation ( Figure 4B ). These findings indicate that tanshinone IIA induces Akt phosphorylation via the PI3K/Akt pathway. To confirm the involvement of Akt signaling pathway in tanshinone IIA survival actions, we next determined whether tanshinone IIA modified their degree of phosphorylation/activation in our experimental conditions. Figure 4C illustrates that incubation with tanshinone IIA enhanced Akt phosphorylation in cultures treated with Ang II. Compared with control cultures, Ang II alone did not modify Akt phosphorylation.
Role of Akt in the protective effect of tanshinone IIA on Ang IIinduced cardiomyocyte apoptosis To identify the signaling pathways involved in the effect of tanshinone IIA, Akt siRNA, which mitigates the kinase activity of Akt, was transfected into cardiomyocytes. The Akt pro- Figure 5A ). The inhibitory effect of tanshinone IIA on the Ang II-induced caspase-3 activation was partially reversed by Wort (100 nmol/L), LY (10 nmol/L), and Akt siRNA ( Figure  5B) . Similarly, the inhibitory effect of tanshinone IIA on Ang II-induced cardiomyocyte apoptosis was reduced by Wort (100 nmol/L), LY (10 nmol/L), and Akt siRNA ( Figure 5C ). These results revealed the involvement of the Akt signaling pathway in tanshinone IIA's effect on Ang II-induced cardiomyocyte apoptosis. The results of our study demonstrated that Ang II caused cardiomyocyte apoptosis; this finding is consistent with that of previous studies and shows that Ang II acts as an efficient inducer of apoptosis in adult and neonatal cardiomyo cytes [5, 6] . A statistically significant reduction of TUNEL-positive cardiomyocytes was observed when tanshinone IIA was added to Ang-II treated cells. Bcl-x L plays important roles in apoptotic cell death, whereas caspase-3 is a key downstream effector of apoptosis. To investigate the underlying mechanism(s) of the antiapoptotic effect of tanshinone IIA, we examined the expression of Bcl-x L and caspase-3. The results showed that tanshinone IIA increased the expression of Bcl-x L . We also found that the caspase-3 activity of myocardial cells was significantly increased when cells were treated with Ang II and that tanshinone IIA greatly reduced this activation. The expression of Bcl-x L and caspase-3 was consistent with the results obtained by TUNEL staining with flow cytometry.
Tanshinone IIA is the main effective component of Salvia miltiorrhiza known as 'Danshen' in traditional Chinese medicine. Clinical evidence has shown that tanshinone IIA increases coronary blood flow and protects the heart against cardiac injury [17] . On the basis of the cardioprotective action of tanshinone IIA, we investigated the hypothesis that tanshinone IIA may prevent the death of cardiomyocytes. Cardiomyocyte apoptosis is one of the major pathogenic mechanisms underlying myocardial injury. Blocking the apoptotic process could prevent the loss of contractile cells and minimize cardiac injury induced by injury, thereby slowing down or even preventing the occurrence of heart failure [18] . Therefore, we performed TUNEL staining in order to explore the underlying mechanism responsible for the improvement of the cardiac function induced by tanshinone IIA. The results indicated that tanshinone IIA inhibited cardiomyocyte apoptosis induced by Ang II; this finding was similar to that of previous studies, which reported that tanshinone IIA protected cardiomyocytes against oxidative stress-triggered damage and apoptosis [8, 18] . The possible mechanisms, which have been proposed for explaining the protective effects of tanshinone IIA, include antioxidant properties involving scavenging of free radicals in cardiomyocytes [7] . In addition, Akt, a serine/threonine kinase, is a primary mediator of the downstream effects of PI3K, which coordinates a variety of intracellular signals and regulates cell proliferation and survival. Recent studies have also shown that activation of the PI3K/Akt signaling pathway protects the myocardium from myocardial injury and prevents cardiomyocyte apoptosis [12] . In order to explore whether the protective effects of tanshinone IIA are associated with the Akt pathway, Akt siRNA was employed to compare the effects of co-administration of Akt siRNA and tanshinone IIA with the effects of administration of tanshinone IIA alone. Pretreatment with PI3K inhibitors (Wort and LY) or transfection with Akt siRNA abolished the cardioprotective effects of tanshinone IIA. These results suggest that tanshinone IIA induces cardioprotective effects through the activation of the Akt-pathway. The results of this study suggest that tanshinone IIA may offer a practicable approach to reduce apoptosis of cardiomyocytes and may merit further investigation. The present study strongly demonstrated that tanshinone IIA protects neonatal cardiomyocytes from Ang II-induced apoptosis. Tanshinone IIA might potentially be used to treat heart failure or other apoptosis-related heart diseases if further studies were performed to define and clarify the rationale for its clinical use.
